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diseasesAbstract Background: Diffuse parenchymal lung diseases (DPLD) constitute a heterogeneous
group of lung diseases characterized by varying degrees of inﬂammation and ﬁbrosis. In some
DPLD, signiﬁcant morbidity and unfavorable evolution, comparable to those of neoplastic dis-
eases, are seen. Therefore, an efﬁcient and safe method for the diagnostic conﬁrmation of DPLD
is needed. Currently, thoracoscopic lung biopsy is widely used for this purpose.
Aim of work: The objective of the present study was to analyze the role of medical thoracoscopic
lung biopsy, in the diagnosis of different types of diffuse parenchymal lung diseases.
Patients and methods: This study included 55 patients with undiagnosed DPLD who were
selected from Chest Department inpatients, Kasr Alaini Hospital during the period from June
2013 to August 2015. All patients were subjected to written informed consent, full medical history,
detailed clinical examination, coagulation proﬁle, echocardiography, immune and collagen proﬁle,
arterial blood gases analysis, spirometry, high resolution computed tomography (HRCT) of the
chest and medical thoracoscopic lung biopsy.
Results: Out of the 55 patients included in the study, 32 (58.2%) were females, 23 (41.8%) were
males, 14 (25.5%) were smokers, 12 (21.8%) had history of raising birds and 12 (21.8%) had positive
collagen proﬁle. The mean age was 39.96 years (range, 10–67). HRCT showed different patterns of
parenchymal affection in addition to mediastinal lymph node enlargement in 8 (14.5%) patients, and
pleural effusion in 11 (20%) patients. Deﬁnitive diagnosis was made in 54 patients (98.18%) and
idiopathic interstitial pneumonia was the predominant diagnosis (43.64%) followed by DPLD of
known cause (36.36%) then granulomatous DPLD (12.7%) and lastly other rare forms of DPLD
(5.45%). The most common diagnoses were the usual interstitial pneumonia in 9 (16.4%), metastatic
adenocarcinoma in 8 (14.8%), desquamative interstitial pneumonia in 7 (12.7%), hypersensitivity
pneumonitis in 5 (9.1%), non speciﬁc interstitial pneumonia, sarcoidosis and pneumoconiosis each
in 4 (7.3%) cases. The mean duration of intercostal tube insertion was 3.4 days. No reported
mortality and complications included prolonged air leak in 4 patients, residual pneumothorax after
removal of intercostal tube in 1 patient, and subcutaneous emphysema in 2 patients.
718 S. Ahmed et al.Conclusions: Lung biopsy through medical thoracoscopy is a safe, effective and viable procedure
for the diagnosis of diffuse parenchymal lung diseases.
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Diffuse parenchymal lung diseases constitute a heterogeneous
group of lung diseases, including more than two hundred dif-
ferent interstitial diseases and characterized by varying degrees
of inﬂammation and ﬁbrosis. These non-neoplastic disorders
primarily affect the lung interstitium, although the
alveolar space, bronchioles and pulmonary vessels can also
be affected [1].
The process of diagnosing a DPLD is dynamic. The diag-
nostic reasoning is based on the joint analysis of clinical, radi-
ological and pathological aspects [1]. Frequently, the deﬁnitive
diagnosis of DPLD can be established only through patholog-
ical examination of the material obtained by lung biopsy. In
addition to diagnostic conﬁrmation, this procedure provides
information regarding disease activity, disease progression
and response to therapy [2].
The options for lung biopsy include bronchoscopy with
transbronchial biopsy, open lung biopsy and lung biopsy
through video-assisted thoracoscopy. Bronchoscopy with
transbronchial biopsy is useful in cases in which the disease
presents peribronchial or peribronchiolar distribution. One
limitation of this procedure is the small quantity of lung tissue
obtained in the biopsy, which is why it is not recommended for
the investigation of idiopathic interstitial pneumonia. In addi-
tion, its accuracy in the diagnosis of DPLD in immunocompe-
tent patients is only 7–37% [3].
The gold standard for the diagnosis of DPLD is surgical
lung biopsy, which should be used whenever it is not possible
to establish a deﬁnitive diagnosis based on the available clini-
cal and radiological data [4]. It can be performed as an open
procedure or through video-assisted thoracoscopy. Open lung
biopsy has a high diagnostic yield (92%), as well as low rates
of morbidity and mortality (2.5% and 0.3%, respectively)
[5]. Video-assisted thoracoscopy is considered a minimally
invasive technique. It provides excellent visualization of the
intra-thoracic structures and allows the collection of a greater
number of lung samples, when necessary. Since it is a less inva-
sive procedure, video-assisted thoracoscopy has come to be
used as the principal mean of diagnosing DPLD. However,
its use must be evaluated in terms of safety and diagnostic res-
olution [5].
While thoracoscopic surgery is rapidly replacing standard
thoracotomy in the evaluation and management of many pleu-
ropulmonary diseases, thoracoscopic lung biopsy is becoming
the procedure of ﬁrst choice for the diagnosis of many local-
ized and diffuse lung diseases and an adjunct to conventional
bronchoscopic evaluation [6,7].
Forceps lung biopsy during thoracoscopy under local anes-
thesia has been used for many years by pulmonologists and has
been frequently described as an integral technique of the
method deﬁned today as medical thoracoscopy [8]. Therefore,
the objective of the present study was to analyze the role of this
currently widely used method, which is medical thoracoscopiclung biopsy, in the diagnosis of different types of diffuse
parenchymal lung diseases.Patients and methods
The present study was conducted on 55 patients with diffuse
parenchymal lung disease admitted in Chest Department, Kasr
El-Aini Hospital, Cairo University during the period from
June 2013 to August 2015. All patients of DPLD on HRCT
chest with unproved diagnosis and of different ages, regardless
the gender, were included in the study. Patients with severe
hypoxia, Type II respiratory failure, severe pulmonary hyper-
tension, coagulopathy (prothrombin concentration 6 50% or
platelet count 6 7000/ml), cardiac disorders (arrhythmia, MI,
unstable angina) or end stage systemic disease were excluded
from the study.
All patients were subjected to written informed consent, full
medical history, including smoking and occupational history,
history of raising birds, detailed clinical examination, coagula-
tion proﬁle (prothrombin concentration and platelet count),
echocardiography, immune and collagen proﬁle, arterial blood
gas analysis, spirometry, high resolution computed tomogra-
phy of the chest and medical thoracoscopic lung biopsy.
Medical thoracoscopic lung biopsy
Equipment
Rigid thoracoscope with a cold light source was used using
KARL-STORZ rigid thoracoscope, coagulation diathermy
forceps and diathermy apparatus.
Technique
The patients were fasting for at least 6 h before the procedure
with the explanation of the procedure to each patient. The pro-
cedure was performed in the endoscopy suit. Pre-medications
in the form of atropine 1 mg IM injection to control vasovagal
tone and Pethidine 100 mg (50 mg IM, 50 mg IV injection) to
ensure proper control of pain and good analgesia were given.
The vital signs of the patients were monitored (blood pressure,
heart rate respiratory rate) during the procedure; also oxygen
saturation was measured by pulse oximetry with spontaneous
ventilation during the procedure. Supplementary oxygen was
provided to the patient to maintain oxygen saturation above
90%.
The patient was placed in the lateral decubitus position
with side that will be operated upon up and the arms above
the head. The lateral chest wall at the side of entry (4th or
5th intercostals space, midaxillary line) was sterilized with
iodo-povidone antiseptic solution. The skin, subcutaneous tis-
sues, periosteum of the ribs and parietal pleura at site of entry
were inﬁltrated by lidocaine 2% as local anesthesia.
Skin incision about 1 cm was made at the planned thoraco-
scopic insertion point. Blunt dissection with round ended
Table 1 Characteristics of the study patients.
Character Number
(total = 55)
Percent
(100%)
Female 32 58.2
Male 23 41.8
Smoking history 14 25.5
History of raising birds 12 21.8
Positive immune and collagen proﬁle 12 21.8
Predominant HRCT pattern
Consolidation 12 21.8
Cystic lesion 1 1.8
Ground glass opacities 12 21.8
Ground glass and air trapping 3 5.5
Military shadows 3 5.5
Nodular lesion 8 14.5
Reticulonodular shadows and ﬁbrosis 14 25.5
Reticulonodular shadows and air trapping 2 3.6
Mediastinal lymph node enlargement 8 14.5
Pleural eﬀusion 11 20
Other systems aﬀection 8 14.5
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trocar (8 mm) was gently advanced thorough the chest wall
until the pleural cavity was reached then the inner part of
the trocar was removed to allow the induction of pneumotho-
rax with lung collapse. The rigid thoracoscope (Karl-storz
Endoscopy, Germany) was passed through the trocar port.
The parietal, visceral pleurae and lung were examined. The
electro-coagulation biopsy forceps connected to diathermy
coagulation (Olympus DSD 20) was passed through the work-
ing channel of the rigid thoracoscopy then the forceps was
dipped in the lung surface in an open position then closed
and lung biopsies were taken while applying short pulses of
diathermy (adjusted at 60 W coagulation). Usually 2–3 biop-
sies were obtained from different lobes.
At the end of the procedure, a chest tube connected to
under water seal was inserted in place and ﬁxed to the skin
of the patient at its exit from the chest wall by a suture after
removal of the port cannula.
Post thoracoscopy care and follow up
All patients were followed post procedure for vital signs, oxy-
gen saturation, chest tube drainage including air leak and ﬂuid
or blood drainage if present. Patients were given broad spec-
trum antibiotic and potent analgesics. Also chest X-ray was
done for conﬁrmation of full lung expansion. When the lung
is fully expanded with the absence of air leak and ﬂuid drai-
nage less than 100 ml/24 h, the tube was removed with or with-
out pleurodesis according to the situation.
Histopathological examination
The biopsy specimens were preserved in formalin containing
cups and sent for histopathological examinations were the
specimens were stained with hematoxylin and eosin stains
and examined under light microscopy. Further immunohisto-
chemical studies sometimes were done if needed (e.g. to differ-
entiate between adenocarcinoma and other epithelial tumors).
Additional tests were done according to the clinical situa-
tion e.g.; CT abdomen and pelvis, tumor markers, upper
GIT endoscopy or colonoscopy to search for primary neo-
plasm. Bone scan, CT brain or pelvi-abdominal sonar were
done to assess distant metastasis.
Statistical analysis
Quantitative data were presented as minimum, maximum,
mean and standard deviation (±SD) values. Qualitative data
were presented as frequencies (number of cases) and percent-
ages. Chi square (v2) test was used to determine signiﬁcant
association between different qualitative variables. All statisti-
cal calculations were done using computer program SPSS (Sta-
tistical Package for the Social Science; SPSS Inc., Chicago, IL,
USA) release 15 for Microsoft Windows (2006).
Results
This study included 55 patients with DPLD on HRCT chest
with unconﬁrmed diagnosis who were selected from chest
department inpatients, Kasr Alaini Hospital during the period
from June 2103 to August 2015. Their ages ranged from 10 to67 years with a mean value of 39.96 and ±SD 13.31. They
included 32 (58.2%) females and 23 (41.8%) males. Among
the study population, 14 (25.5%) patients were smokers, 12
(21.8%) patients had history of raising birds and also 12
(21.8%) patients had positive collagen proﬁle (Table 1).
Regarding the HRCT chest ﬁndings, there were different
patterns of parenchymal affection in addition to mediastinal
lymph nodes enlargement in 8 (14.5%) patients, pleural effu-
sion in 11 (20%) patients as shown in Table 1. Also other sys-
tems affection was present in 8 (14.5%) patients (Table 1). The
arterial blood gases and spirometric data are listed in Table 2.
Regarding the lung biopsy side, lung biopsies were obtained
from the right lung in 38 (69.09%) patients and from the left
lung in 17 (30.91%) patients according to the HRCT predom-
inant pattern and avoiding areas with extensive ﬁbrosis and
honeycombing.
The different histopathological types of DPLD based on
thoracoscopic lung biopsy results were shown in Table 3.
Deﬁnitive diagnosis was obtained in 54 patients (98.18%)
and idiopathic interstitial pneumonia was the predominant
diagnosis (in 24 cases with percent of 43.64) followed by
DPLD of known cause (in 20 cases with a percent of 36.36)
then granulomatous DPLD (in 7 cases with a percent of
12.7) and lastly other rare forms (Fig. 2) of DPLD (in 3 cases
with a percent of 5.45). The most common diagnoses were
usual interstitial pneumonia in 9 (16.4%), metastatic adenocar-
cinoma in 8 (14.8%) (Fig. 1), desquamative interstitial pneu-
monia in 7 (12.7%), hypersensitivity pneumonitis in 5
(9.1%), non speciﬁc interstitial pneumonia, sarcoidosis and
pneumoconiosis each in 4 (7.3%) cases.
The duration of intercostals tube insertion post procedure
ranged from 2 to 10 days with a mean value of 3.4 days and
±SD 1.63. No reported mortality and complications occurred
only in 7 (12.7%) patients including prolonged air leak in 4
patients which stopped spontaneously with no further interfer-
ence, residual pneumothorax after removal of intercostal tube
in 1 patient, and subcutaneous emphysema in 2 patients.
Table 2 Arterial blood gases parameters & spirometric data
of the study patients.
Character Number (%) Mean ± SD
PaO2 mm Hg 55 (100) 62.04 ± 7.90
PaCO2 mm Hg 55 (100) 37.95 ± 4.55
SaO2% 55 (100) 91.38 ± 3.69
FVC% 55 (100) 57.13 ± 21.37
FEV1% 55 (100) 55.82 ± 17.99
FEV1/FVC% 55 (100) 90.11 ± 10.18
FEF25–75% 55 (100) 47.82 ± 13.69
Table 3 Spectrum of diagnoses of DPLD according to
histopathology results of thoracoscopic lung biopsy.
Histopathology type Number Percent
Idiopathic interstitial pneumonias: 24 (43.64%)
Cryptogenic organizing pneumonia 3 5.5
Desquamative interstitial pneumonia 7 12.7
Non speciﬁc interstitial pneumonia 4 7.3
Usual interstitial pneumonia 9 16.4
Pleuroparenchymal ﬁbroelastosis 1 1.8
Granulomatous DPLD: 7 (12.7%)
Sarcoidosis 4 7.3
Pulmonary tuberculosis 2 3.6
Weagner’s granulmatosis 1 1.8
DPLD of known cause: 20 (36.36%)
Hypersensitivity pneumonitis 5 9.1
Metastatic adenocarcinoma 8 14.5
Pneumoconiosis 4 7.3
Exogenous lipoid pneumonia 2 3.6
Pneumocystis Carinii Pneumonia 1 1.8
Other forms of DPLD: 3 (5.45%)
Idiopathic pulmonary hemosiderosis 1 1.8
Alveolar proteinosis 1 1.8
Pulmonary Langerhan’s Cell histocytosis 1 1.8
Undiagnosed
Chronic non speciﬁc inﬂammation 1 1.8
Total 55 100%
Figure 1 Female patient 24 year old complaining of fever, dry
cough and exertional dyspnea, 3 months ago. HRCT chest
(picture A) showed widespread nodular inﬁltration and ground
glass opaciﬁcation with some reticulations. Picture B showing the
coagulation biopsy forceps taking punch from lung tissue.
Picture C showing area of scar in the lung surface after taking a
biopsy. Histopathology result of lung biopsy showed ‘‘metastatic
signet ring cell carcinoma variant of adenocarcinoma”. Upper and
lower gastrointestinal endoscopies were done searching for
primary and revealed primary gastric signet ring cell carcinoma.
Figure 2 37 year old male patient complaining of gradual
progressive exertional dyspnea and dry cough of 7 months
duration. HRCT (picture A) showed crazy paving appearance.
Picture B showing anthracotic lung surface with the coagulation
biopsy forceps taking punch from lung tissue. Picture C showing
area of scar in the lung surface after taking biopsy. Histopathol-
ogy result of lung biopsy showed alveolar proteiniosis.
720 S. Ahmed et al.Discussion
The DPLDs constitute a heterogeneous group of lung diseases
characterized by varying degrees of inﬂammation and ﬁbrosis.
In some DPLDs, signiﬁcant morbidity and unfavorable evolu-
tion, comparable to those of neoplastic diseases, are seen.
Therefore, an efﬁcient and safe method for the diagnostic con-
ﬁrmation of DPLD is needed [9].
Lung biopsy is required for diagnosis in about one third of
patients with diffuse inﬁltrative disease. Transbronchial biopsy
is less painful, less invasive, and considerably less costly, com-
pared with open or thoracoscopic procedure, and entails a
lower incidence of mortality and of morbidity [10]. However,
transbronchial biopsy has introduced new diagnostic problems
for the pathologist because the specimen has all the features
that open biopsy tries to avoid: it is unselected and exceedingly
small, the lung tissue is crushed and it comes from regions
immediately adjacent to bronchi.Lung biopsy under vision has higher diagnostic yield when
compared to transbronchial lung biopsy [11]. The British
Thoracic Society (BTS) guidelines suggest that it should be
Thoracoscopic lung biopsy for diffuse parenchymal lung diseases 721standard practice to take lung biopsy samples in DPLD when
the diagnosis remains uncertain after clinical and radiological
assessments, unless there are patient contraindications or
when the samples are very unlikely to contribute to
management [12].
The aim of the present study was to evaluate the role of
medical thoracoscopic lung biopsy as a tool in the diagnosis
of different types of diffuse parenchymal lung diseases.
This study included 55 patients with undiagnosed DPLD
who were subjected to medical thoracoscopic lung biopsy.
The study population showed predominance of females
(58.2%) over males (32%). These result matched with those
of Abdollah (2012) [13] who performed medical thoracoscopic
lung biopsies in 10 patients with DPLD and found that females
(60%) were predominant over males (40%). Similarly study of
Ishie et al. (2009) [9] showed predominance of females
(52.08%) over males (47.92%). However, other authors have
found a slight predominance of males [14].
The mean age of DPLD patients in this study was
39.9 years with ±SD 13.3 years. This ﬁnding is similar to those
reported by Abdollah (2012) [13] who found that the mean age
in their study was 42.2 with ±SD 9.5 years. On the other hand
Vansteenkiste et al. (1999) [15] found that the mean age was
52.3 ± SD 16.7 years.
In the present study, a deﬁnitive diagnosis was obtained in
54 (98.18%) out of the 55 studied patients and the idiopathic
interstitial pneumonia was the predominant diagnosis (in 24
cases with percent of 43.64) followed by DPLD of known
cause (in 20 cases with a percent of 36.36) then granulomatous
DPLD (in 7 cases with a percent of 12.7) and lastly other rare
forms of DPLD (in 3 cases with a percent of 5.45). The higher
prevalence of diseases was belonging to usual interstitial pneu-
monia (UIP) in 9 (16.4%) cases, metastatic adenocarcinoma in
8 (14.8%) cases, desquamative interstitial pneumonia (DIP) in
7 (12.7%) cases, hypersensitivity pneumonitis in 5 (9.1%)
cases, non speciﬁc interstitial pneumonia (NSIP), sarcoidosis
and pneumoconiosis each in 4 (7.3%) cases.
These results matched with those of Nitin et al. (2011) [16]
who reported that UIP (59.3%) was the most frequent
histopathological pattern within 63 patients involved in their
study. While Abdollah [13] found that out of 10 patients, 3
(30%) of them had metastatic adenocarcinoma, one patient
with chronic pulmonary infection and 6 (60%) patients with
interstitial lung disease (ILD) divided as 2 patients had UIP,
3 patients had DIP and 1 Patient had NSIP.
Dijkman et al. (1982) [17] study included 63 cases, 57
(90.48%) cases of them were diagnosed with medical thora-
coscopy. The most common diagnoses were UIP in 17 cases,
sarcoidosis in 7 cases, lymphangitic carcinoma in 5 cases, eosi-
nophilic pneumonia in 3 cases and histocytosis X in 5 cases.
Also in Andrew et al. (2002) [18] study which included 62
patients, diagnoses were obtained in 61 (98.39%) patients;
the most common diagnoses were neoplasm in 25 patients
(40%), interstitial lung disease in 18 patients (29.5%) and
granulomatous disease in 7 patients.
In the literature, the prevalence of hypersensitivity pneumo-
nia ranges from 1.5% to 14%. Similarly, the prevalence of
pneumoconiosis ranges from 4% to 10.4% [19].
In this study sarcoidosis was found in only 4 cases (7.3%).
In contrast, in the literature, sarcoidosis is described as a
common DPLD. In a study involving 3152 patients [20],sarcoidosis was the most common disease (in 33.72% of the
cases), followed by idiopathic pulmonary ﬁbrosis (in 27.41%
of the cases). This is due to the fact that sarcoidosis, due to
its characteristic peribronchial or peribronchiolar distribution,
is preferably diagnosed by transbronchial biopsy [21]. There-
fore, in suspected cases of sarcoidosis, surgical lung biopsy is
used only when the diagnosis cannot be made by trans-
bronchial biopsy.
In the present study, medical thoracoscopy provided ade-
quate lung tissue samples with high diagnostic efﬁcacy. The
deﬁnitive diagnosis was made in 98.18% of the cases. This
ﬁnding is in agreement with the studies performed by Nitin
et al. (2011) [16], Abdollah (2012) [13] and Vansteenkiste
et al. (1999) [15] where the diagnostic yield in their studies
was 98.3%, 90% and 91%, respectively.
Overall no reported mortality, major complication, or pro-
longed post-thoracoscopic hospital stay and this agreed with
that of Abdollah (2012) [13] who concluded in their study that
medical thoracoscopic lung biopsy is safe, feasible and useful
technique in the diagnosis of DPLD.
In conclusion, this study illustrated that medical thora-
coscopy with lung biopsy is an effective and safe procedure
in the hands of well trained interventional pulmonologists.
Depending on institutional habits and local expertise, it can
be an interesting, and probably less expensive in diagnostic
work-up of DPLD. The analysis of the results of our study
revealed that, as long as there is an investigation and appropri-
ate pre-planning, as well as careful selection of candidates,
medical thoracoscopy is an option with a good success rate
when adequate lung biopsy is indicated.Conﬂict of interest
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